Medtronic's Ishrak: Renal denervation hasn't caught on yet in Europe

Medtronic ($MDT) has generated plenty of buzz about its renal denervation technology, which is designed to deaden the nerves in the kidneys to combat drug-resistant hypertension. But the company has had trouble negotiating reimbursement for the therapy in Europe, where it has had approval since 2010. As Reuters reports, Medtronic CEO Omar Ishrak explained that as a result, the company has experienced limited adoption of the technology in the European market. Ishrak, speaking at the Reuters Health Summit this week, said the slow adoption is because the technology is so new and not a "conventional part of the healthcare system yet." Ishrak said additional studies now under way will help to build support for the technology over time and help "different administrators to decide how it fits." Story

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.